332 related articles for article (PubMed ID: 19018782)
1. Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditis.
Heemstra KA; Hoftijzer HC; van der Deure WM; Peeters RP; Fliers E; Appelhof BC; Wiersinga WM; Corssmit EP; Visser TJ; Smit JW
Clin Endocrinol (Oxf); 2009 Aug; 71(2):279-83. PubMed ID: 19018782
[TBL] [Abstract][Full Text] [Related]
2. The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density.
Heemstra KA; Hoftijzer H; van der Deure WM; Peeters RP; Hamdy NA; Pereira A; Corssmit EP; Romijn JA; Visser TJ; Smit JW
J Bone Miner Res; 2010 Jun; 25(6):1385-91. PubMed ID: 20200941
[TBL] [Abstract][Full Text] [Related]
3. A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters.
Peeters RP; van den Beld AW; Attalki H; Toor Hv; de Rijke YB; Kuiper GG; Lamberts SW; Janssen JA; Uitterlinden AG; Visser TJ
Am J Physiol Endocrinol Metab; 2005 Jul; 289(1):E75-81. PubMed ID: 15727947
[TBL] [Abstract][Full Text] [Related]
4. Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients.
Torlontano M; Durante C; Torrente I; Crocetti U; Augello G; Ronga G; Montesano T; Travascio L; Verrienti A; Bruno R; Santini S; D'Arcangelo P; Dallapiccola B; Filetti S; Trischitta V
J Clin Endocrinol Metab; 2008 Mar; 93(3):910-3. PubMed ID: 18073314
[TBL] [Abstract][Full Text] [Related]
5. No Effect of the Thr92Ala Polymorphism of Deiodinase-2 on Thyroid Hormone Parameters, Health-Related Quality of Life, and Cognitive Functioning in a Large Population-Based Cohort Study.
Wouters HJ; van Loon HC; van der Klauw MM; Elderson MF; Slagter SN; Kobold AM; Kema IP; Links TP; van Vliet-Ostaptchouk JV; Wolffenbuttel BH
Thyroid; 2017 Feb; 27(2):147-155. PubMed ID: 27786042
[TBL] [Abstract][Full Text] [Related]
6. The effect of genetic variation in the type 1 deiodinase gene on the interindividual variation in serum thyroid hormone levels: an investigation in healthy Danish twins.
van der Deure WM; Hansen PS; Peeters RP; Uitterlinden AG; Fenger M; Kyvik KO; Hegedüs L; Visser TJ
Clin Endocrinol (Oxf); 2009 Jun; 70(6):954-60. PubMed ID: 18793344
[TBL] [Abstract][Full Text] [Related]
7. Impact of thyroid function and polymorphisms in the type 2 deiodinase on blood pressure: the Rotterdam Study and the Rotterdam Scan Study.
van der Deure WM; Peeters RP; Uitterlinden AG; Hofman A; Breteler MM; Witteman J; Visser TJ
Clin Endocrinol (Oxf); 2009 Jul; 71(1):137-44. PubMed ID: 19178511
[TBL] [Abstract][Full Text] [Related]
8. DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient Patients.
Castagna MG; Dentice M; Cantara S; Ambrosio R; Maino F; Porcelli T; Marzocchi C; Garbi C; Pacini F; Salvatore D
J Clin Endocrinol Metab; 2017 May; 102(5):1623-1630. PubMed ID: 28324063
[TBL] [Abstract][Full Text] [Related]
9. The Thr92Ala 5' type 2 deiodinase gene polymorphism is associated with a delayed triiodothyronine secretion in response to the thyrotropin-releasing hormone-stimulation test: a pharmacogenomic study.
Butler PW; Smith SM; Linderman JD; Brychta RJ; Alberobello AT; Dubaz OM; Luzon JA; Skarulis MC; Cochran CS; Wesley RA; Pucino F; Celi FS
Thyroid; 2010 Dec; 20(12):1407-12. PubMed ID: 21054208
[TBL] [Abstract][Full Text] [Related]
10. Type 2 deiodinase Thr92Ala polymorphism is associated with disrupted placental activity but not with dysglycemia or adverse gestational outcomes: a genetic association study.
Dora JM; Wajner SM; Costa JD; Pinto Ribeiro RV; Leiria LB; Lopes MG; Vitali da Silva A; Crispim D; Maia AL
Fertil Steril; 2014 Mar; 101(3):833-9. PubMed ID: 24355051
[TBL] [Abstract][Full Text] [Related]
11. Type 2 Deiodinase Thr92Ala Polymorphism and Aging Are Associated with a Decreased Pituitary Sensitivity to Thyroid Hormone.
Luongo C; De Stefano MA; Ambrosio R; Volpe F; Porcelli T; Golia V; Bellevicine C; Troncone G; Masone S; Damiano V; Matano E; Klain M; Schlumberger M; Salvatore D
Thyroid; 2023 Mar; 33(3):294-300. PubMed ID: 36680751
[No Abstract] [Full Text] [Related]
12. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
[TBL] [Abstract][Full Text] [Related]
13. The Asp727Glu polymorphism in the TSH receptor is associated with insulin resistance in healthy elderly men.
Peeters RP; van der Deure WM; van den Beld AW; van Toor H; Lamberts SW; Janssen JA; Uitterlinden AG; Visser TJ
Clin Endocrinol (Oxf); 2007 Jun; 66(6):808-15. PubMed ID: 17408423
[TBL] [Abstract][Full Text] [Related]
14. Determination of Frequency of Type 2 Deiodinase Thr92Ala Polymorphism (rs225014) in
Gawandi S; Jothivel K; Kulkarni S
Indian J Nucl Med; 2024; 39(1):24-28. PubMed ID: 38817730
[TBL] [Abstract][Full Text] [Related]
15. Lack of association between serum TSH or free T4 and body mass index in euthyroid subjects.
Manji N; Boelaert K; Sheppard MC; Holder RL; Gough SC; Franklyn JA
Clin Endocrinol (Oxf); 2006 Feb; 64(2):125-8. PubMed ID: 16430708
[TBL] [Abstract][Full Text] [Related]
16. The type 2 deiodinase ORFa-Gly3Asp polymorphism (rs12885300) influences the set point of the hypothalamus-pituitary-thyroid axis in patients treated for differentiated thyroid carcinoma.
Hoftijzer HC; Heemstra KA; Visser TJ; le Cessie S; Peeters RP; Corssmit EP; Smit JW
J Clin Endocrinol Metab; 2011 Sep; 96(9):E1527-33. PubMed ID: 21715540
[TBL] [Abstract][Full Text] [Related]
17. The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe.
de Jong FJ; Peeters RP; den Heijer T; van der Deure WM; Hofman A; Uitterlinden AG; Visser TJ; Breteler MM
J Clin Endocrinol Metab; 2007 Feb; 92(2):636-40. PubMed ID: 17105838
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiological relevance of deiodinase polymorphism.
Bianco AC; Kim BS
Curr Opin Endocrinol Diabetes Obes; 2018 Oct; 25(5):341-346. PubMed ID: 30063552
[TBL] [Abstract][Full Text] [Related]
19. Thyroxine replacement dose in patients with Hashimoto disease: a potential role for interleukin-6.
Papanas N; Papazoglou D; Papatheodorou K; Antonoglou C; Kotsiou S; Maltezos E
Cytokine; 2006 Aug; 35(3-4):166-70. PubMed ID: 16949834
[TBL] [Abstract][Full Text] [Related]
20. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer.
Montesano T; Durante C; Attard M; Crocetti U; Meringolo D; Bruno R; Tumino S; Rubello D; Al-Nahhas A; Colandrea M; Maranghi M; Travascio L; Ronga G; Torlontano M
Biomed Pharmacother; 2007 Sep; 61(8):468-71. PubMed ID: 17553654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
